The pharmaceutical factory is changing. For decades, quality decisions were often made after the event: after a batch record was reviewed, after laboratory results were returned, after a deviation was raised, or after a trend was identified during periodic review. Today, the growth of connected manufacturing systems, automated process controls, electronic batch records, manufacturing execution systems, environmental monitoring platforms and advanced analytics is changing that model.
In the connected factory, Quality Assurance is no longer limited to reviewing quality after production has taken place. QA teams can increasingly access real-time data that shows how a process is performing while it is happening. This is reshaping how quality decisions are made, how risks are detected, and how organisations build confidence in their manufacturing processes.
For pharmaceutical companies, this is not simply a digital transformation story. It is a quality transformation story.
From Retrospective Review to Real-Time Oversight
Traditional pharmaceutical quality systems rely heavily on retrospective review. Batch documentation, laboratory testing, deviation investigations and periodic product quality reviews remain essential, but they often provide insight after an issue has already occurred.
Real-time data changes the timing of quality decision-making. Instead of waiting for a batch to finish before identifying problems, connected systems can provide early warning signals. These may include process drift, equipment performance changes, environmental monitoring alerts, temperature excursions, pressure variations, cleaning cycle anomalies, weighing discrepancies or unusual operator interventions.
This does not remove the need for QA judgement. In fact, it increases the importance of QA judgement. Real-time data can highlight a potential issue, but QA must determine its quality significance, regulatory impact and required response.
The value lies in moving from a reactive model to a more proactive one.
What Is a Connected Factory?
A connected factory is a manufacturing environment where equipment, systems and data sources are linked in a way that supports greater visibility, control and decision-making. In pharmaceutical manufacturing, this may include:
- Manufacturing execution systems
- Electronic batch records
- Laboratory information management systems
- Process analytical technology
- Environmental monitoring systems
- Building management systems
- Equipment sensors and automation platforms
- Digital quality management systems
- Deviation, CAPA and change control platforms
- Data historians and analytics dashboards
When these systems are properly integrated and validated, they can provide a more complete view of manufacturing performance. Instead of separate teams looking at isolated data sets, the organisation can begin to understand how process, equipment, environment, materials and human factors interact.
This wider visibility is particularly important in complex manufacturing environments, including sterile manufacturing, biologics, high-potency products and continuous manufacturing.
Real-Time Data and Quality Risk Management
Quality risk management is central to modern pharmaceutical manufacturing. Real-time data strengthens that approach by giving QA teams better evidence for identifying, assessing and controlling risk.
For example, if a process parameter begins trending towards an action limit, the connected factory can give teams an opportunity to assess the situation before a deviation occurs. If environmental monitoring data shows a recurring pattern in a particular area, QA can investigate potential causes earlier. If equipment data suggests a decline in performance, maintenance and quality teams can intervene before the issue affects product quality.
This type of visibility supports more informed decision-making. It also helps organisations distinguish between isolated events and emerging trends.
However, the presence of more data does not automatically mean better quality. The key question is whether the data is reliable, meaningful and properly governed. Poorly configured systems, weak data integrity controls or unclear alarm strategies can create confusion rather than clarity.
Data Integrity Remains Non-Negotiable
As pharmaceutical companies become more digital, data integrity becomes even more important. Real-time data only has value if it can be trusted.
Regulators continue to emphasise the importance of complete, consistent and accurate data in GMP environments. In a connected factory, this means organisations must consider system validation, audit trails, access controls, electronic signatures, time stamps, data review procedures, backup arrangements and cybersecurity controls.
EU GMP Annex 11 applies to computerised systems used as part of GMP-regulated activities and makes clear that the use of computerised systems should not reduce product quality, process control or quality assurance. FDA data integrity guidance also reinforces that data must be reliable and accurate to support CGMP decisions.
For QA, this creates a critical responsibility. QA must be involved not only in reviewing the outputs of digital systems, but also in ensuring that those systems are validated, controlled and fit for their intended use.
Faster Decisions, Better Investigations
One of the most significant benefits of real-time data is its ability to improve investigations. Deviation investigations can be time-consuming when data is fragmented across paper records, spreadsheets, laboratory systems and equipment logs. Connected systems can make it easier to reconstruct what happened, when it happened and what else may have contributed.
For example, a deviation in a filling line may be easier to investigate when QA can review linked data from equipment alarms, environmental monitoring, operator actions, batch record entries and maintenance history. A temperature excursion may be assessed more effectively when the time, duration, affected materials and alarm response are visible in one controlled system.
This can support faster root cause analysis, more targeted CAPA and stronger product impact assessments.
It can also reduce the risk of decisions being based on incomplete information.
The Connected Factory and Batch Release
Real-time data is also changing the conversation around batch release. While final release decisions remain governed by GMP, product specifications, documentation review and qualified person or quality unit responsibilities, connected systems can make the release process more efficient and evidence-based.
Electronic batch records can reduce manual transcription errors, highlight missing entries, flag exceptions and support review by exception. Process monitoring tools can provide greater confidence that critical parameters remained within defined limits. Laboratory and production data can be linked more effectively to support faster review.
In more advanced manufacturing environments, including continuous manufacturing, real-time monitoring and control strategies may play an even greater role in demonstrating process control. FDA has continued to support advanced manufacturing approaches that can improve manufacturing reliability, robustness and product quality.
The direction of travel is clear: quality release decisions are becoming more data-rich, more connected and, where properly controlled, more efficient.
Why QA Must Be Involved Early
The connected factory cannot be built as an IT project alone. It must be built as a quality project.
QA must be involved early in decisions about system selection, validation strategy, data governance, user access, audit trail review, alarm management, record retention and change control. Without QA involvement, organisations risk implementing digital systems that generate large volumes of data but do not adequately support GMP decision-making.
Important questions include:
- What data is GMP-critical?
- Which parameters are critical to quality?
- Who is responsible for reviewing alerts and exceptions?
- How are alarms categorised, escalated and documented?
- How are audit trails reviewed?
- What happens when systems fail, or data is incomplete?
- How are digital changes assessed and approved?
- How is data protected from unauthorised alteration?
- How are personnel trained to use and interpret system outputs?
These questions must be addressed before systems go live, not after the first inspection or deviation.
Avoiding Data Overload
A connected factory can produce enormous volumes of data. The challenge is not simply collecting data; it is turning data into useful quality intelligence.
Too many alarms can lead to alarm fatigue. Too many dashboards can dilute attention. Poorly defined metrics can create a false sense of control. QA teams need clear governance around what data matters, how it is reviewed, and how it supports decision-making.
The goal should not be to monitor everything equally. The goal should be to focus on the data that has the greatest relevance to product quality, process control and patient safety.
This is where QA can provide leadership. By applying risk-based thinking, QA can help organisations prioritise critical data, define meaningful thresholds and ensure that digital monitoring supports the pharmaceutical quality system rather than overwhelming it.
People Still Make the Quality Decisions
Real-time data can transform quality decision-making, but it does not replace experienced quality professionals. Data can show what is happening. It can identify trends, flag exceptions and support investigations. But human expertise is still needed to interpret context, assess risk and decide the appropriate action.
The connected factory, therefore, changes the role of QA rather than reducing it. QA professionals need to become more data-literate, more comfortable with digital systems and more involved in cross-functional decision-making. They must understand not only GMP, but also how data flows through the manufacturing environment.
This creates new expectations for quality teams. It also creates opportunities for organisations that invest in the right skills, systems and culture.
Final Thought
The connected factory is changing pharmaceutical quality assurance from a retrospective function into a more proactive, data-driven discipline. Real-time data can help organisations detect risk earlier, investigate issues faster, improve process understanding and make better quality decisions.
However, the benefits are only realised when the data is reliable, validated and governed within a strong pharmaceutical quality system.
For pharmaceutical companies, the message is clear: digital transformation must be quality-led. The connected factory is not just about smarter equipment or better dashboards. It is about making more informed decisions that protect product quality, compliance and patient safety.
In the future of pharmaceutical manufacturing, quality will not simply be reviewed at the end of the process. It will be monitored, understood and protected in real time.